This company has been acquired
Surface Oncology Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Surface Oncology.
Key information
9.9%
Earnings growth rate
9.9%
EPS growth rate
| Biotechs earnings growth | 26.8% |
| Revenue growth rate | 75.6% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 08 Sep 2023 |
Recent future growth updates
Recent updates
Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically
Nov 07
Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts
Aug 08Surface Oncology GAAP EPS of -$0.46 misses by $0.01
Aug 03Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline
May 25News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts
May 11Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 23Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
Jan 18Is Surface Oncology (NASDAQ:SURF) A Risky Investment?
Nov 11Surface Oncology: Staying The Course
Oct 24Surface Oncology: A Diverse, But Early Pipeline
Jul 13Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?
Jun 07Surface Oncology EPS beats by $0.04, beats on revenue
May 05Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like
Mar 15Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 16
Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets
Dec 09What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?
Dec 08Surface Oncology shares rise 13% on Fast Track tag for SRF388
Nov 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 16 | -75 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -90 | N/A | N/A | 2 |
| 12/31/2023 | N/A | -90 | N/A | N/A | 1 |
| 6/30/2023 | N/A | -93 | -84 | -84 | N/A |
| 3/31/2023 | N/A | -90 | -60 | -59 | N/A |
| 12/31/2022 | 30 | -64 | -60 | -60 | N/A |
| 9/30/2022 | 30 | -66 | -54 | -54 | N/A |
| 6/30/2022 | 31 | -63 | -50 | -50 | N/A |
| 3/31/2022 | 31 | -57 | -67 | -67 | N/A |
| 12/31/2021 | 3 | -78 | -62 | -62 | N/A |
| 9/30/2021 | 90 | 13 | 26 | 26 | N/A |
| 6/30/2021 | 90 | 17 | 31 | 31 | N/A |
| 3/31/2021 | 89 | 21 | 27 | 27 | N/A |
| 12/31/2020 | 126 | 59 | 30 | 30 | N/A |
| 9/30/2020 | 39 | -24 | -56 | -56 | N/A |
| 6/30/2020 | 39 | -25 | -60 | -60 | N/A |
| 3/31/2020 | 40 | -28 | -58 | -57 | N/A |
| 12/31/2019 | 15 | -55 | -62 | -60 | N/A |
| 9/30/2019 | 25 | -44 | -63 | -61 | N/A |
| 6/30/2019 | 26 | -44 | -61 | -58 | N/A |
| 3/31/2019 | 28 | -35 | -65 | -63 | N/A |
| 12/31/2018 | 59 | -7 | -15 | -13 | N/A |
| 9/30/2018 | 52 | -18 | -15 | -14 | N/A |
| 6/30/2018 | 53 | -15 | -12 | -11 | N/A |
| 3/31/2018 | 57 | -13 | 21 | 22 | N/A |
| 12/31/2017 | 13 | -45 | -14 | -12 | N/A |
| 9/30/2017 | 12 | -36 | -13 | -11 | N/A |
| 12/31/2016 | 7 | -17 | N/A | 41 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SURF is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SURF is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SURF is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SURF is forecast to have no revenue next year.
High Growth Revenue: SURF is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SURF's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/09 13:41 |
| End of Day Share Price | 2023/09/07 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Surface Oncology, Inc. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Ulz | Baird |
| Justin Zelin | BTIG |
| Joshua Schimmer | Evercore ISI |